CN1270749C - Bone impediment convalescence capsule - Google Patents
Bone impediment convalescence capsule Download PDFInfo
- Publication number
- CN1270749C CN1270749C CNB2005100174841A CN200510017484A CN1270749C CN 1270749 C CN1270749 C CN 1270749C CN B2005100174841 A CNB2005100174841 A CN B2005100174841A CN 200510017484 A CN200510017484 A CN 200510017484A CN 1270749 C CN1270749 C CN 1270749C
- Authority
- CN
- China
- Prior art keywords
- portions
- capsule
- present
- bone
- convalescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 13
- 208000034657 Convalescence Diseases 0.000 title claims abstract description 8
- 241000272074 Bungarus Species 0.000 claims description 5
- 241001057584 Myrrha Species 0.000 claims description 5
- 239000009286 sanguis draxonis Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 36
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 241000272060 Elapidae Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 239000000843 powder Substances 0.000 description 12
- 208000007875 Femur Head Necrosis Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000003128 head Anatomy 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 206010002027 Amyotrophy Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 206010031264 Osteonecrosis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 210000004394 hip joint Anatomy 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001446509 Psoralea Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000037873 arthrodesis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a bone impediment convalescence capsule which is characterized in that the bone impediment convalescence capsule is prepared by using raw materials in the following proportions by weight: 100 to 110 portions of myrrh, 58 to 65 portions of saffron, 84 to 90 portions of multibanded kraits, 80 to 85 portions of Sanguis Draconis, 84 to 90 portions of eucommia barks and 94 to 100 portions of hemlock parsley. The capsule of the present invention has the efficacies of vitality movement, smooth blood circulation, and meridian and collateral clearing. The present invention is an ideal medicine for the adjuvant treatment of ischemic femoral head necrosis.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine, relate to a kind of bone impediment convalescence capsule that is used for the treatment of ischemic necrosis of femoral head disease specifically.
Background technology
Ischemic necrosis of femoral head is meant because the different causes of disease causes capital disturbance of blood circulation, makes femoral head that the pathological process of part or completeness ischemia take place.This patient is more common in 30-50 year, and has half to involve bilateral femoral head.Motherland's medical science is thought, ischemic necrosis of femoral head belongs to " osteomyelitis " category, its main pathogenesis be caused by liver and kidney deficiency, qi depression to blood stasis, bone lose moisten foster, or hindered by violence, or the infection excessive QI, or sexual strain, or the natural endowment deficiency, its clinical manifestation is symptoms such as the hip arthralgia, limping, function limitation, lower limb muscles atrophy, until the forfeiture self care ability.Owing to after the collapse of the femoral head distortion, often cause the hip joint handicap, therefore more and more be subjected to the attention of medical circle.
At present, the comparatively popular method of western medical treatment primary disease mainly is an operative treatment, and be broadly divided into following two classes: (1) improves the femoral head blood supply: implement synovectomy, core decompression art, vessel pedicle ilium transplantation, vascular bundle implantation; (2) improve the mortar head and contain, improve the femoral head at weight loading position: as distinguishing osteotomy, shelf operation of hip joint between the femoral head rotor.Other is also being accepted by people gradually as artificial femoral head replacement, replacement of total hip, arthrodesis etc.Above-mentioned various operation all is to reach different curative effects by different means, and clinical manifestation is that the patient is movable better, ambulation in early days, and the hospital stays is shorter.But postoperative is prone to complication such as collapse of the femoral head, the loosening dislocation of artificial thigh bone, cervical region fracture and infection, and is difficult to remedy.Therefore, the patient has doubt more before the art, even can suffer that the patient refuses.
Modern medicine is thought: femur head necrosis is the downright bad caused pathological process of active component (osteocyte, medullary cell and adipose cell) of bone, but up to the present still can not determine the definite reason that causes primary disease.General think relevant with the wound of hip joint, some drugs (as adrenocortical hormone), multiple disease, chronic alcoholism etc. more.The common pathological manifestations of femur head necrosis is the unusual of the femoral head disturbance of blood circulation that caused by a variety of causes and joint stress.Motherland's medical science extensive knowledge and profound scholarship, aboundresources, people-oriented, utilizes motherland's traditional medicine, adopts the non-operative treatment ischemic necrosis of femoral head, and expense is lower, and no pain, and treating both the principal and secondary aspects of a disease has caused the great attention of medical circle in recent years, and has obtained gratifying achievement.Clinical pharmacology studies show that: Chinese medicine is applicable to the overall process of primary disease treatment, and its effect comprises the blood circulation that improves bone, and blood flow increasing reduces intra-osteal pressure, and anticoagulant alleviates the osteonecrosis degree, promotes effects such as osteonecrosis reparation.Current research finds that also Chinese medicine also has the angiogenic growth of promotion and the effect of protection circulation.
Summary of the invention
The objective of the invention is to for the treatment of treatment ischemic necrosis of femoral head disease provides a kind of blood circulation promoting and blood stasis dispelling that has, the dredge the meridian passage effect, and can alleviating pain, ancillary drug---the bone impediment convalescence capsule of improved therapeutic effect that expense is lower.
Purpose of the present invention can realize by following measure:
Bone impediment convalescence capsule of the present invention is to join part feedstock production of ratio by following weight to form, Myrrha 100-110 part wherein, Stigma Croci 58-65 part, Bungarus Parvus 84-90 part, Sanguis Draxonis 80-85 part, Cortex Eucommiae 84-90 part, Rhizoma Chuanxiong 94-100 part.
Prescription analysis of the present invention is as follows:
Myrrha, blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain are monarch drug.Stigma Croci, sweet, flat, blood circulation promoting and blood stasis dispelling, the dissipating blood stasis relieving accumulation of pathogens is gone into blood system, the meridian dredging; Bungarus Parvus, outer thorough skin, the interior internal organs of walking, wind-damp dispelling, saturating muscles and bones, arresting convulsion is jerked, and getting it, deep merit of searching wind is arranged is ministerial drug with the meridian dredging; Sanguis Draxonis, sweet salty, flat, dissipating blood stasis analgesic therapy, hemostasia and promoting granulation; Cortex Eucommiae invigorating the liver and kidney is an adjuvant drug to moisten the nourishing muscle and tendon bone.Rhizoma Chuanxiong, suffering, temperature, activating QI to alleviate the depression, dispeiling pathogenic wind and removing dampness, promoting blood circulation and stopping pain is messenger drug.
Take a broad view of full side, it is smooth to have a gas promoting the circulation of blood, and the effect of dredge the meridian passage is the ideal medicament of auxiliary treatment ischemic necrosis of femoral head disease.
Clinical drug of the present invention is observed and is tested as follows:
Clinical observation: 100 examples, wherein the men and women is each 50.
Clinical manifestation: local red and swollen, twinge, painful have the place of deciding, becoming severe at night, complexion is dark, and hair quality is dark red, deep pulse, tcm diagnosis is a qi stagnation and blood stasis type.Western medicine diagnose is a local pain, or radiated pain; Waist is to strong lateral bending song: " 4 " word is levied (+); The pelvis separation test positive; Amyotrophy; X-ray film, CT sheet show the clinical manifestation of fracture, osteonecrosis.
Curative effect determinate standard is recovery from illness, produce effects, effective three types:
Recovery from illness: conscious pain, numbness, amyotrophy are eliminated, and functional rehabilitation is normal, and activity freely.
Produce effects: pain, numbness, amyotrophy are eliminated or basic the elimination, but still have the mild pain feeling of numbness, and function is accessible substantially, can adhere to work.
Effectively: pain, numbness, amyotrophy have comparatively significantly improvement.
The present invention is according to conditions of patients, the medicine that cooperates bone erosion renewel pill, Psoralea pill and the treatment Avascular Necrosis Of Femur Head of selecting the separate case application for use, clinical efficacy shows: medicine of the present invention is an ancillary drug as treatment ischemic necrosis of femoral head disease, obey patient's day 1 time, each 4, through medication treatment, its effect is: the femur head necrosis cure rate is 35%, obvious effective rate is 60%, total effective rate 95%, invalid 5%.Do not find untoward reaction.This medicine also has better curative effect to prolapse of lumbar intervertebral disc simultaneously.Through to 100 prolapse of lumbar intervertebral disc patients medication, per diem obey 1 time, each 4, its curative effect shows: cure rate is 70%, and obvious effective rate is 24%, total effective rate 94%, invalid 6%.
Great new medicine science and technology development test result is as follows through Henan for the drug effect of medicine of the present invention, acute toxicity test:
Acute toxicity test: with medicine of the present invention be equivalent to clinical medicine 120 extraordinarily pure water be mixed with suspension, give mouse stomach, a continuous week observes, outward appearance, action activity, the mental status, diet, drinking-water, feces, fur, the colour of skin, breathing are all normal, the no abnormal secretions in nose, eye and oral cavity, acute toxic reaction and death do not appear, healthy survival.
Long term toxicity test: with medicine of the present invention be equivalent to clinical medicine 50～30 extraordinarily pure water be mixed with suspension, give rat oral gavage, 3 months test periods (clinical 1 month) observe, the figure does not have pathology and changes, and slowness toxicity do not occur and changes.
The test of pesticide effectiveness: be mice, rat paw, ears, blood capillary, the administration respectively of two axil otch, cause inflammation, pain and swelling etc., with clinical drug dosage of the present invention 10～20 extraordinarily pure water be mixed with suspension, give rat oral gavage, with be equivalent to the clinical application amount 12.5～25 extraordinarily pure water be mixed with suspension, give mouse stomach, observed, and proved that medicine of the present invention had tangible detumescence, antiinflammatory, analgesic activity in continuous 7 days.
The specific embodiment
The present invention does with detailed description below with reference to embodiment:
Embodiment 1:
Present embodiment adopts following proportioning and processing step to realize:
A, get Stigma Croci 59g by weight, pulverize, sieve with pulverizer, flour extraction is 96%～98%, drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, drug powder seal storage after the sterilization treatment, standby;
B, with Myrrha 100g, Bungarus Parvus 90g, Sanguis Draxonis 82g, Cortex Eucommiae 89g, after Rhizoma Chuanxiong 100g mixes, pulverize, sieve with pulverizer, the drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, and its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, the drug powder seal storage after the sterilization treatment, standby;
C, two groups of drug powders of a, b are placed in the three-dimensional mixer fully mix, after the vacuum dryer drying, be ground into fine powder again, drop into automatical loading machine for capsules afterwards and be processed into capsule.
Embodiment 2:
Present embodiment adopts following proportioning and processing step to realize:
A, get Stigma Croci 65g by weight, pulverize, sieve with pulverizer, flour extraction is 96%98%, drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 10000-15000/g reduce to 100/below the g, drug powder seal storage after the sterilization treatment, standby;
B, with Myrrha 110g, Bungarus Parvus 85g, Sanguis Draxonis 83g, Cortex Eucommiae 84g, after Rhizoma Chuanxiong 95g mixes, pulverize, sieve with pulverizer, the drug powder after will pulverizing afterwards carries out sterilization treatment with 100 ℃ of flowing steams, and its time was controlled between 25～40 minutes, make antibacterial by 10000-100000/g reduce to 500/below the g, mycete by 1000-1500/g reduce to 100/below the g, the drug powder seal storage after the sterilization treatment, standby;
C, two groups of drug powders of a, b are placed in the three-dimensional mixer fully mix, after the vacuum dryer drying, be ground into fine powder again, drop into automatical loading machine for capsules afterwards and be processed into capsule.
Claims (1)
1, a kind of bone impediment convalescence capsule is characterized in that: the composition of effective ingredient and weight proportion thereof are in this capsule: Myrrha 100-110 part, Stigma Croci 58-65 part, Bungarus Parvus 84-90 part, Sanguis Draxonis 80-85 part, Cortex Eucommiae 84-90 part, Rhizoma Chuanxiong 94-100 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100174841A CN1270749C (en) | 2005-04-01 | 2005-04-01 | Bone impediment convalescence capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100174841A CN1270749C (en) | 2005-04-01 | 2005-04-01 | Bone impediment convalescence capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686219A CN1686219A (en) | 2005-10-26 |
| CN1270749C true CN1270749C (en) | 2006-08-23 |
Family
ID=35304261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100174841A Expired - Fee Related CN1270749C (en) | 2005-04-01 | 2005-04-01 | Bone impediment convalescence capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270749C (en) |
-
2005
- 2005-04-01 CN CNB2005100174841A patent/CN1270749C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686219A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181453B (en) | Chinese medicine preparation for curing orthopaedics sickness | |
| CN1319569C (en) | Chinese medicine preparation for treating osteoporosis and fracture and preparation process thereof | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN1270749C (en) | Bone impediment convalescence capsule | |
| CN101904958B (en) | Oral medicinal composition for treating fracture | |
| CN1907410A (en) | Chinese traditional medicine preparation for treating bone fracture and traumatic injury | |
| CN1270741C (en) | Psoralea pill | |
| CN104225034B (en) | Application of composition in preparing medicine for treating non-infectious urethral syndrome | |
| CN102743499B (en) | Chinese medicinal herb drug for treating soft tissue internal injury blood stasis and cerebral hemorrhage and method for preparing same | |
| CN106880701A (en) | A kind of compound osteitis bar cloth pastes the preparation method of Chinese medical concrete | |
| CN1270730C (en) | Channels sootheing and network vessel quickening pill for treating protrasion of lumbar intervertebral disci | |
| CN1318080C (en) | Medicine used for treating osteonecrosis, femur ischemic osteonecrosis | |
| CN120392893B (en) | A traditional Chinese medicine composition for promoting intestinal function recovery in patients undergoing abdominal surgery, and its preparation method and use | |
| CN104258113B (en) | A kind of Chinese medicine composition for the treatment of cerebral hemorrhage | |
| CN1320900C (en) | Bone erosion renewel pill | |
| CN1284579C (en) | Oral medicine for treating ischemic necrosis of femoral head and its preparation | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN115844972B (en) | Umbilical patch for treating osteoporosis and preparation method thereof | |
| CN100353995C (en) | Pharmaceutical composition with functions of dispersing pathogenic wind, activating collaterals ,and clearing away toxin | |
| CN102327407A (en) | Traditional Chinese medicine for treating femoral head necrosis and preparation method thereof | |
| CN102218094A (en) | Chinese medicinal preparation for treating traumatic injury and preparation method thereof | |
| CN1709458A (en) | Medicine for treating coronary clisease | |
| CN120478539A (en) | Pharmaceutical composition for treating fracture and preparation method and application thereof | |
| CN103520282B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN105232703B (en) | A kind of Chinese medicine composition and its preparation method and application for treating cervical spondylotic myelopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060823 |